The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy
Journal of Gastrointestinal Cancer · 2025
DOI: 10.1007/s12029-024-01118-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal Cancer, 2025. Verfasst von Abhinav K Rao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Trident Medical Center, 9330 Medical Plaza Dr, North Charleston, SC, 29406, USA. abhirao.md@gmail.com. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonoscopy, Early Detection of Cancer, Feces. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Multitarget stool DNA (MT-sDNA) tests (here, Cologuard®) are currently used in average-risk patients as a primary method of screening for colorectal cancer. However, MT-sDNA testing has also been used in patients who previously underwent colonoscopy who wish to avoid repeat colonoscopy. Here, in a large primary care practice setting, our aim was to evaluate the diagnostic performance of MT-sDNA testing in patients with a previously normal colonoscopy. METHODS: This retrospective cohort study included 5827 patients from 35 different primary locations in South Carolina. Patients aged 45 and above with a previously documented normal, high-quality colonoscopy prior to the MT-sDNA test date were included. High-risk patients and those with a previous negative MT-sDNA result were excluded. RESULTS: Of 5827 ordered MT-sDNA tests, 248 patients had a prior normal colonoscopy. The average time from initial colonoscopy to MT-sDNA testing was 7.3 years. Of the 63 patients who had a positive MT-sDNA test, 41 patients (65%) completed follow-up colonoscopy and 40 patients had complete colonoscopy data. Of these 40 patients, 12 patients (30%) had advanced adenomas and none had colorectal cancer. Compared to patients without a previous colonoscopy, patients with prior colonoscopies had fewer adenomas of all types (1.6 vs 2.4) and fewer advanced adenomas (1.4 vs 2.0). CONCLUSION: Patients with a previously negative colonoscopy and subsequent positive MT-sDNA test were found to have a high rate of advanced adenomas on follow-up colonoscopy (30%). Thus, in patients with a previously negative colonoscopy, MT-sDNA testing may be a reasonable alternative screening option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Trident Medical Center, 9330 Medical Plaza Dr, North Charleston, SC, 29406, USA. abhirao.md@gmail.com.
- Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC, USA. abhirao.md@gmail.com.
- Department of Internal Medicine, Trident Medical Center, 9330 Medical Plaza Dr, North Charleston, SC, 29406, USA.
- Division of Gastroenterology, Trident Medical Center, North Charleston, SC, USA.
- Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC, USA.
Zitieren
APA
Rao, A. K., Kalra, S., Van Leer-Greenberg, B., & Rockey, D. C. (2025). The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01118-3
Vancouver
Rao AK, Kalra S, Van Leer-Greenberg B, Rockey DC. The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy. Journal of Gastrointestinal Cancer. 2025. doi:10.1007/s12029-024-01118-3
BibTeX
@article{Rao2025,
author = {Rao, Abhinav K and Kalra, Shivam and Van Leer-Greenberg, Brett and Rockey, Don C},
title = {The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy},
journal = {Journal of Gastrointestinal Cancer},
year = {2025},
doi = {10.1007/s12029-024-01118-3}
}
EUVIMED